




The format and/or content of this presentation is copyright © 2019 by Coding
Strategies, Inc. (CSI). It
is illegal to reproduce
and/or distribute in any
form any part of this
presentation without written permission.

2

Disclaimer

- When a third-party payer is involved, the determination of reimbursement for services is the decision of the individual insurance company based on the patient's policy and the third-party payer guidelines. No guidance can adequately address reimbursement issues for the hundreds of insurance payers that exist. Efforts have been made to ensure the information was valid at the date of presentation. Reimbursement policies vary from insurer to insurer and the policies of the same payer may vary within different U.S. regions. All policies should be verified to ensure compliance. Therefore, it is essential that each payer be contacted for their individual requirements. The websites listed in this presentation are current and valid as of the date of this presentation. However, webpage addresses and the information on them may change or disappear at any time and for any number of reasons. The attendee is encouraged to confirm or locate any URLs listed here that are no longer valid.
- are no longer valid.
- are no longer valud. CPT® codes, descriptions and other data are copyright 2018 American Medical Association (or such other date of publication of CPT®). All Rights Reserved. CPT® is a registered trademark of the American Medical Association. Code descriptions and billing scenarios are references from the AMA, CMS local and national coverage determinations (LCD/NCD).and standards nationwide.






Pederal Register Document actions of Federal agencies and forum for public review and comment Publications include: Presidential Documents, Rule & Regulations, Proposed Rules and Notices Hospital Outpatient Prospective Payment System (HOPPS) (Includes QPP) REVENSE A general Register Medicare Physician Fee Schedule (MPFS) (Includes QPP)

5

Proposed vs. Final Rule Proposed Rule: CMS plans, goals, solutions to problems and proposed rulemaking Opportunity for public to make comments Final Rule: Final legal effect after consideration of comments Opportunity for public to make comments Final Rule: Final legal effect after consideration of comments Opportunity for public to make comments



Appropriate Use Criteria

- · Introduced in PAMA
- Utilization of Appropriate Use Criteria (AUC) for advanced diagnostic studies
 - CT
 - MR
 - Nuclear Medicine including PET

REVENU

Copyright® 2017 CSI All Rights Reserved

8

Appropriate Use Criteria

CMS can only approve the AUC that are developed or endorsed by provider-led entities (PLEs)

- Must be evidence based
- Listing is on CMS's website

Once a PLE is "qualified" all of the AUC developed or endorsed by that PLE are considered to be "specified AUC" for the purposes of the requirements.

REVENUE

CODINGSTRATEG

Clinical Decision Support

8 priority clinical areas

- Coronary artery disease (suspected or diagnosed)
- Suspected pulmonary embolism
- Headache (traumatic and non-traumatic)
- Hip pain
- Low back pain
- Shoulder pain (to include suspected rotator cuff)
- Cancer of the lung (primary or metastatic, suspected or diagnosed)
- Cervical or neck pain





10

Clinical Decision Support

- Ordering physician must access AUC through a Clinical Decision Support Mechanism (CDSM)
- · CDSM is an electronic portal
 - Module in an EHR
 - Web-based system
- CDSM will pull information about the patient from the EHR and/or the ordering physician will enter the information and immediate feedback will be provided re: appropriateness of exam





11

Approved Support Mechanisms

Qualified Clinical Decision Support Mechanisms as of June 2018

Cuatantee Cunical Decision Support Nacchanisms as of J.
Alf. Specially Health ProvidesPratial's
Against Sathmays CURION** Platform
Crathery Peaks act Callison Support Mechanism
Medical Cilisical Decision Support Company, CaraSelect**
National Tecknism Support Company, CaraSelect**
National Technism Support Company, CaraSelect

*Free Tool Available


Copyright® 2018 CSI All Rights Reserved/Copyright®2018 RCI All Rights Reserved Copyright®2018 RCI All Rights Reserved Copyright Reserved

Clinical Decision Support

- Requirement is that AUC must be consulted
- · Radiologists will not be exempt
- Does not apply to inpatient, certain emergency studies or to ordering physicians who qualify for a hardship exception
 - There are no hardships for furnishing professionals
 - CAHs are exempt
- Ordering professionals must communicate the results of the consultation to the imaging provider
 - Facility & Radiologist



13





14

Implementation Timeline

- · Original implementation was January 1, 2017
- . CDS delayed in 2016-2018 Final Rules
- New implementation date of January 1, 2020 testing period of 1 year
 - Mandatory implementation date of 1/1/21
- · Voluntary reporting period of 7/2018 12/2019
 - Early adopters can begin to submit data to CMS
 - Identifier will not be ready yet so CMS created the QQ modifier

€ Poor		
REVENUE	Copyright® 2019 CSI All Rights Reserved Copyright® 2019 RCI All Rights Reserved CPT celly ® 2019 American Medical Association All Rights Reserved	⊘ CODINGSTRATEGIE







17


New Reporting Requirements Required beginning 1/1/2020 1 G-code required on the claim per mechanism Modifiers to be assigned at the CPT code level indicating adherence to the utilized AUC Adhered, Not Adhered, Not applicable Many operational concerns with these requirements How will you communicate this information to the imaging providers?

18

REVENUE







What do we Know?

- Effective 1/1/20 imaging providers (including Oncologists that own and perform diagnostic studies) must report a G code at the claim level and a modifier at the line item level for designated exams
 - Multiple G codes may be on the same claim
- Facilities *cannot* perform this for the referring physicians
- Referring physicians can have their own clinical staff perform at their direction

REVENUE

(A CODINCSTDA

22



23

Additional Questions...

- Will CDS be required when Medicare is the secondary payer?
- How does the CDS consultation requirement apply to observation patients?
- What will happen to modifier MH in 2021?

REVENUE

●CODINGSTRATEG


Next Steps • Specifically clarify your organization's issues and concerns • Have a clear plan to address • Learn from others – good, bad & ugly • Watch for more CMS updates and incorporate into your plans


25



26








29



Accept To Receive CDSN This is the # that will potentially ultimately be submitted with the claim Will be linked to this specific exam within the master CMS database/registry Case submitted successfully Your decision support number is: 70778179 Back to Care-Select

31



32





Medically Reasonable / Necessary

- · Medical Record must demonstrate
 - "... support (of) the intensity and frequency of the E/M service met but that it *did not exceed* the patient's clinical needs."
 - '...the patient's condition is the key factor in determining medical necessity."

REVENU

CODINGSTRATE

35

Where's the Money?


Incorrectly or mistakenly coding a medical service will likely lead to an uptick in claims denials, so healthcare organizations should regularly train clinical staff on ICD-10 coding updates and encourage front-end staff to communicate with clinicians if there are documentation issues.

REVENU


26


Incomplete Information – Unspecified . CMS: LCDs and NCDs that contain ICD-10 codes for right side, left side or bilateral do not allow for unspecified side. (i.e., will be denied) · Conditions frequently assigned unspecified codes Alcohol and drug use, abuse and dependence Asthma Alzheimer's disease Arthritis Atrial Fibrillation Atrial flutter Congestive heart failure Intestinal obstruction Non-pressure ulcers/ Pressure Cardiomyopathy Cerebral palsy Epilepsy Migraines Neoplasms ulcers Sepsis Strokes Traumatic injuries

37



38





Teaching Physician E/M Changes

2018

- Medical record must document that the teaching physician was present at the time the service is furnished.


 Teaching physician must document extent of participation in the review and direction of services furnished to each beneficiary.


2019


- Medical record must document teaching physician was present during procedures and E/M services and may be documented by physician, nurse or resident by notes in medical record.
- medical record.

 Medical record must document extent of teaching physician's participation in review and direction of services furnished and the extent can be demonstrated by the notes in medical record made by physician, resident or nurse.


41








44





Medically Appropriate History/PE

(A) Removing history and examination as key components for selecting the level of E/M service, but adding the requirement that a medically appropriate history and/or examination must be performed in order to report codes 99202-99215;

Read full summary for additional details on changes to E/M codes 99202-99215


REVENUE

47

MDM or Time

(B) Making the basis for code selection either the level of medical decision making (MDM) performed or the total time spent performing the service on the day of the encounter;


REVEN



Estimated 2021 Payment Rates TABLE 24B: Comparison of 2018 and 2021 Estimated National Payment Amounts for Visits Complexity Either Primary or specialized care add-on code* Visit Code Visit Code New Extended Services Code Level 2 \$76 \$110 \$130 \$143 \$197 Level 3 Level 5 \$211 Level 2 \$45 \$74 \$103 \$157 Level 3 \$90 Level 4 Level 5 \$148 \$149 REVENUE

50

Code	Specialized Complexity	
GCG0X	Visit complexity inherent to evaluation and management associated with endocrinology inheumatology, hereantology(noclogy, urology, neurology, obstetrics/gynecology allergy/immunology, oblanyngology, cardiology, or inheventional pain management centered care (Add-on code, list separately in addition to an evaluation an management visit)	
Applies to:	Anyone who performed a visit and as part of the visit discussed a treatment plan etc. related to the additional specialties identified by the code	
Example:	Oncologist sees patient discusses cancer diagnosis and the treatment plan including surgical and chemotherapy options. Physician reports the specialty add-on code and physician's specialty reported on claim form and medical record supports diagnosis and clinician's assessment and plan	
Code	Prolonged Services	
GPRO1	(Protonged evaluation and management or psychotherapy service(s) (beyond the typical service time of the primary procedure) in the office or other outpatient setting requiring direct patient contact beyond the usual service; 30 minutes (List separately in addition to code for office or other outpatient Evaluation and Management or psychotherapy service)	
Applies to:	Only billable with level 2-4 visit codes	



AMA CPT® Editorial Panel Updates CY 2020 & 2021

Name - Office or Other Outpatient Services

- Code # D99201 ▲99213 ▲99202 ▲99214 ▲99203 ▲99215 ▲99204 ▲99205 ▲99211 ▲99212
- Effective Date January 1, 2021
- Description of Editorial Panel Action
 - Accepted deletion of code 99201
 - · Revision of codes 99202-99215

https://www.ama-assn.org/system/files/2019-03/february-2019-summary-panelactions 0.pdf

RECOLD

RECOLD

Supplement SIGN Right Record Copyr 2018 DO Night R


53

CAR T-cell Therapy Codes

- (CAR) T-cell therapy is cell-based gene therapy, T-cells are collected and genetically engineered to express a chimeric antigen receptor that will bind to a certain protein on a patient's cancerous cells.
- CAR T-cells are administered to the patient to attack certain cancerous cells and observed for potential serious side effects that would require medical intervention.

REVENUE
CYCLE. Copyright 2019 CSI Al Rights Ris

OCODINGSTRATEGIE



Modifiers 59 and X Update

Modification of the MCS Claims Processing System Logic for Modifier 59, XE, XS, XP, and XU Involving the National Correct Coding Initiative (NCCI) Procedure to Procedure (PTP) Column One and Column Two Codes, Effective July 1, 2019

https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/downloads/MM11168.pdf

REVENUE

56

MM11168

PROVIDER TYPE AFFECTED

This MLN Matters® Article is for physicians, providers, and suppliers submitting claims to Medicare Administrative Contractors (MACs) for services to Medicare beneficiaries.

PROVIDER ACTION NEEDED

CR11168 informs MACs about changes to National Correct Coding Initiative (NCCI) Procedure to Procedure (PTP) edits which consist of column one and column two codes. Make sure that your billing staffs are aware of these changes

BACKGROUND

Modifiers 59, XE, XS, XP, and XU are among the NCCI-associated modifiers. The Multi-Carrier System (MCS) currently requires that modifiers 59, XE, XS, XP, or XU be appended to the column two code of a PTP edit to bypass the edit. With the implementation of CR 11188, Medicare will allow modifiers 59, XE, XS, XP, or XU on column one and column two codes to bypass the edit.



57

MM11296 Ten (10) new HCPCS codes will be payable for Medicare, effective for claims with dates of service on or after July 1, DESCRIPTION J1444 Fe pyro cit pow 0.1 mg iron J7208 Inj. jivi 1 iu Revefenacin inh non-com 1mcg J7677 J9030 Bcg live intravesical 1mg J9036 Inj., belrapzo/bendamustine J9356 Inj. herceptin hylecta, 10mg Q5112 Inj ontruzant 10 mg Q5113 Inj herzuma 10 mg Q5114 Inj ogivri 10 mg Q5115 Inj rituximab-abbs bio 10 mg


58

MM11296 cont.

- HCPCS code J9031 (Bcg (intravesical) per instillation), no longer reimbursed, effective for claims with dates of service on or after July 1, 2019
- The long and short descriptors for HCPCS code J9355 will be modified, effective for claims with dates of service on or after July 1, 2019,
 - J9355 Short Descriptor: Inj trastuzumab excl biosimi
 - J9355 Long Descriptor: Injection, trastuzumab, excludes biosimilar, 10 mg

REVENUE
COpyright* 2019 CSI All Rights Reserved Copyright* 2019 RCI All Rights Reserved CPT celly * 2019 American Medical Asso

59



Melody W. Mulaik, MSHS, CRA, RCC, RCC-IR, CPC, COC Melody.Mulaik@CodingStrategies.com	
REFERENCE Copyright 2010 CSM Inglis Interved Copyright 2010 ICSM I	